EBOS board affirms compliance and solvency in interim financial declaration

EBOS Group Limited ( (AU:EBO) ) has shared an announcement.

EBOS Group Limited’s board has declared that the company’s condensed consolidated interim unaudited financial statements for the six months to 31 December 2025 comply with New Zealand’s External Reporting Board accounting standards and present a true and fair view of its financial position and performance. The directors further state there are reasonable grounds to believe EBOS can meet its debts as they fall due, reinforcing confidence in the group’s financial health and solvency for stakeholders.

The declaration, dated 24 February 2026 and signed by board chairperson E. Coutts on behalf of the directors, formalises the board’s oversight of financial reporting for the interim period and signals governance assurance over EBOS’s accounting practices. This board-level endorsement of compliance and solvency supports market trust in the company’s reporting integrity and its capacity to continue operating without liquidity concerns.

The most recent analyst rating on (AU:EBO) stock is a Hold with a A$26.00 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the AU:EBO Stock Forecast page.

More about EBOS Group Limited

EBOS Group Limited is a diversified healthcare and pharmaceutical company operating across Australia and New Zealand, supplying medicines, medical devices and related services to pharmacies, hospitals and other healthcare providers. The group plays a key role in regional healthcare distribution, with operations spanning wholesale, logistics and related support services for the sector.

Average Trading Volume: 136,505

Technical Sentiment Signal: Sell

Current Market Cap: A$4.29B

See more insights into EBO stock on TipRanks’ Stock Analysis page.